Dr. Shiwei Liu is a biomedical scientist and registered patent agent focusing on global patent prosecution in the life sciences sector. His practice includes drafting and prosecuting patent applications, as well as assisting with patentability assessments and freedom-to-operate analyses, particularly in the areas of antibody-based therapeutics, vaccines, CAR-T and CAR-NK cell technologies, and peptide conjugates.
Shiwei completed his Ph.D. at Harvard Medical School/Harvard University, where his work uncovered a mechanistic link between cancer cell division and genome instability. He then conducted post-doctoral research at Harvard University, where he used genome-scale DNA and RNA microscopy-based imaging to investigate 3D-genome organization in transcriptionally distinct cell types in the brain. He also previously worked in the pharmaceutical industry on gene therapies for human diseases.
Shiwei has authored a number of peer-reviewed publications in journals, including Nature, Science Advances, and Developmental Cell. His work has been cited by more than 2,000 peer-reviewed articles.
- Suffolk University Law School (currently attending law school with expected graduation in 2030); Harvard University (Ph.D. in Biological and Biomedical Sciences 2019); Fudan University (B.S. in Biological Sciences 2012)
- Registered to practice before the United States Patent and Trademark Office
- Mandarin
发送前请注意
*Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice